Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIB hyperlipidemia

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 11, 2002, Pages 4991-5000

  Guerin, Maryse ^a,b   Egger, Pascal ^a,b   Goff, Wilfried Le ^a,b   Soudant, Céline ^a,b   Dupuis, Reynald ^a,b   John Chapman, M ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL ESTER; CHYLOMICRON; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; HEADACHE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MALE; MYALGIA; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHYLOMICRONS; FASTING; FOOD; GLYCOPROTEINS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 0036846531     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020298     Document Type: Article

References (33)

1. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN 1997 The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17:715-722
2. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM, Patsch W 1992 Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12:1336-1345
3. Ordovas JM 2001 Genetics, postprandial lipemia and obesity. Nutr Metab Cardiovasc Dis 11:118-133
4. Weintraub MS, Eisenberg S, and Breslow JL 1989 Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia. Eur J Clin Invest 19:480-485
5. Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH 2000 Postprandial apoB48- and B100-containing lipoproteins in type 2 diabetes: Do statins have a specific effect on triglyceride metabolism? Metabolism 49:1049-1054
6. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJ 1995 Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 44:460-465
7. Sheu WH, Jeng CY, Lee WJ, Lin SY, Pei D, Chen YT 2001 Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism 50:355-359
8. Simo IE, Yakichuk JA, Ooi TC 1993 Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 100:55-64
9. Cohn JS 1994 Postprandial lipid metabolism. Curr Opin Lipidol 5:185-190
10. Burnett JR, Barrett PH, Vicini P, Miller DB, Telford DE, Kleinstiver SJ, Huff MW 1998 The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler Thromb Vasc Biol 18:1906-1914
11. Parhofer KG, Barrett PH, Schwandt P 2000 Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. J Clin Endocrinol Metab 85:4224-4230
12. Jones P, Kafonek S, Laurora I, Hunninghake D 1998 Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587
13. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D 1997 A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 80:39-44
14. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacshon JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM 1996 Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275:128-133
15. Alaupovic P, Heinonen T, Shurzinske L, Black DM 1997 Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis 133:123-133
16. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K 1998 Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 18:783-793
17. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ 2000 Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189-197
18. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG 1973 Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544-1568
19. Arad Y, Ramakrishnan R, Ginsberg HN 1990 Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production. J Lipid Res 31:567-582
20. Lassel TS, Guerin M, Auboiron S, Chapman MJ, Guy-Grand B 1998 Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol 18:65-74
21. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM 1981 A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22:339-358
22. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ 1996 Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 16:763-772
23. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GNI 1998 Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138:217-225
24. Guerin M, Dolphin PJ, Chapman MJ 1994 A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb 14:199-206
25. Funatsu T, Suzuki K, Goto M, Arai Y, Kakuta H, Tanaka H, Yasuda S, Ida, M, Nishijima S, Miyata K 2001 Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis 157:107-115
26. Isusi E, Aspichueta P, Liza M, Hernandez ML, Diaz C, Hernandez G, Martinez MJ, Ochoa B 2000 Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis 153:283-294
27. Foger B, Drexel H, Hopferwieser T, Miesenbock G, Ritsch A, Lechleitner M, Trobinger G, Patsch JR 1994 Fenofibrate improves postprandial chylomicron clearance in IIB hyperlipoproteinemia. Clin Invest 72:294-301
28. Genest J, Nguyen NH, Theroux P, Davignon J, Cohn JS 2000 Effect of micronised fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol 35:164-172
29. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A 2000 Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101:1773-1779
30. Ooi TC, Cousins M, Ooi DS, Steiner G, Uffelman KD, Nakajima K, Simo IE 2001 Postprandial remnant-like lipoproteins in hypertriglyceridemia. J Clin Endocrinol Metab 86:3134-3142
31. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A 1993 Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 91: 748-758
32. Endo A 1992 The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569-1582
33. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM 2000 Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 150:421-428